M
MAP
vs
S
S&P/ASX 300
Over the past 12 months, MAP has underperformed S&P/ASX 300, delivering a return of -62% compared to the S&P/ASX 300's +12% growth.
Stocks Performance
MAP vs S&P/ASX 300
Performance Gap
MAP vs S&P/ASX 300
Performance By Year
MAP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Microba Life Sciences Ltd
Glance View
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
